Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9048-2
Annals of Surgical Oncology 13:1717-1723 (2006)
© 2006 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manci, N.
Right arrow Articles by Panici, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manci, N.
Right arrow Articles by Panici, P. B.

Original Article

Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence: Surgical and Survival Data

Natalina Manci, MD1, Filippo Bellati, MD1, Ludovico Muzii, MD2, Marco Calcagno, MD1, Sagit Arbel Alon, MD1, Milena Pernice, MD1, Roberto Angioli, MD2 and Pierluigi Bendetti Panici, MD1

1 Department of Gynecology and Obstetrics, University of Rome "La Sapienza", V.le Regina Elena, 324, 001161 Rome, Italy
2 Department of Obstetrics and Gynecology, Campus Bio Medico University of Rome, Rome, Italy

Correspondence: Address correspondence and reprint requests to: Natalina Manci, MD; E-mail: natalina.manci{at}uniroma1.it.

Background: Ovarian cancer disease recurs predominantly in the abdomen, with the spleen usually involved as part of a vast spread of upper-abdominal disease or, less frequently, as an isolated site of disease recurrence. Very few reports are available in the literature on the outcome of patients subjected to splenectomy during secondary cytoreduction. The aim of this study was to identify prognostic factors and to review surgical and clinical data in order to identify those patients who would benefit the most from splenectomy during secondary cytoreduction.

Methods: This was a retrospective review of platinum-sensitive recurrent epithelial ovarian cancer patients who underwent splenectomy as part of secondary cytoreduction. Surgical and survival data were recorded.

Results: Twenty-four patients were identified. Multiple site disease recurrence was observed in 15 patients. The spleen was involved at the hilus in 12 patients; surface and intraparenchymal metastases were equally present. Optimal cytoreduction was achieved in all patients. At a median follow-up of 30 months, median progression-free and overall survival from the time of secondary surgery were 34 and 56 months, respectively. Overall survival was significantly correlated to residual disease at secondary surgery, disease-free survival, consolidation chemotherapy, and type of adjuvant therapy.

Conclusions: Splenectomy as part of secondary cytoreduction is a feasible and safe procedure. Secondary cytoreduction in selected groups of patients is confirmed to be associated with high long-term survival rates even when aggressive surgery of the upper abdomen is required.

Key Words: Ovarian cancer recurrence • Secondary cytoreduction • Splenectomy




This article has been cited by other articles:


Home page
 JCOHome page
A. N. Fader and P. G. Rose
Role of Surgery in Ovarian Carcinoma
J. Clin. Oncol., July 10, 2007; 25(20): 2873 - 2883.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of Surgical Oncology.